Surgery is the only treatment for biliary tract cancer with long term survival. Unfortunately, most patients are diagnosed at stage IV with distant metastases. In these circumstances, life expectancy is less than one year due to aggressive tumour biology and a lack of effective systemic therapies. HER2 overexpression or amplification is predominantly seen in extrahepatic cholangiocarcinoma and gallbladder cancer (10-18%) and rarely in intrahepatic cholangiocarcinoma (1%). Trastuzumab is a monoclonal antibody that targets HER-2. We present a clinical case with a stage IV gallbladder cancer (liver and interaortocaval lymph node metastases), which presented progression during first-line chemotherapy treatment, which prompted a change in therapy to study the Her 2/Neu mutation which showed an intense positive overexpression. A combination of HER2/Neu-directed therapy (Trastuzumab) with second-line chemotherapy, was able to achieve a long term complete radiological, metabolic, and biochemical response. A curative intention surgery was performed and the patient is alive and recurrence-free at five years. To the best of our knowledge, we present a case which is the first report of a patient with a Stage IV gallbladder cancer who achieved a five-year survival without recurrence after a conversion therapy combining chemotherapy plus Trastuzumab and radical salvage surgery. 
INTRODUCTION
a life expectancy of less than one year due to aggressive tumour biology and lack of effective systemic therapies. 2 In cases with non-resectable BTC (locally advanced, recurrent, or metastatic), the current standard of care is systemic chemotherapy with gemcitabine and cisplatin. This regimen was established by the ABC-02 trial, the largest randomised phase III study to date, which showed a survival benefit of the combination of gemcitabine and cisplatin opposed to gemcitabine alone (11.7 vs. 9 months). 2 Nevertheless, clinical response rates to these regimens are low, with ＜10% long term survival for all BTC subtypes and a complete response only in exceptional cases. 2 Other chemotherapy combinations (5-Fluoruracile, capecitabine, oxaliplatin, and irinotecan) have only marginal improvements in survival. 3, 4 BTC has multiple potential mutations that could be used as a target for treatment, but there is a significant lack of evidence of such novel therapeutic strategies. 5 Due to this, a greater appreciation of the molecular heterogeneity across the BTC subtypes must be paid, realising that these anatomically classified subgroups (IHCC, EHCC, or GBC) exhibit distinct molecular and potential ther- apeutic strategies (Fig. 1) . 6 (no liver or lymph node metastases), and intense liver multifocal fibrosis. The cystic duct was negative for tumour.
Today, the patient is now recurrence-free at five years.
DISCUSSION
The HER2/neu gene is located on the 17q12-q21 chromosomal region acting as an oncogene in several human cancers. 11 The HER2 gene is a key driver in the development of several solid tumours, including breast, ovarian, and gastric cancer. Overexpression is observed in approximately 20 % of breast/ovarian cancers and 12% of gastric cancers. 12 HER2 overexpression or amplification are predominantly seen in EHCC and GBCs (10-18%), 13 and rarely in IHCC (1%). 14 The prognostic role of HER2 overexpression or amplification is still controversial in BTC.
Some studies failed to demonstrate the prognostic impact of HER2 overexpression, probably due to the relatively small sample size and heterogeneity of the patients studied, 14 while other reports showed that it could be a bad prognosis factor. 15 Trastuzumab is a monoclonal antibody that targets HER2. Javle et al. 16 reported results from a retrospective study with Trastuzumab and concurrent chemotherapy in BTC. HER2 overexpression or amplification was present in eight out of nine GBC and three out of five EHCC.
Moreover, the GBC group with HER2 overexpression or amplification experienced radiological stability in three out of eight cases, partial response in four out of eight, and a complete response in one out of eight. On the other hand, none of the EHCC had a radiological response, concluding that HER2/neu-directed therapy is a promising avenue for patients with GBC with gene amplification. 16 Recently, with the preliminary data from the MyPathway trial, a prospective multicentric phase IIA study, it has been proposed that HER2/neu blockage with Pertuzumab plus Trastuzumab could be a promising treatment strategy for HER2-positive metastatic BTC. In this study, 11 patients with HER2-positive BTC were enrolled. With a median follow-up of 4.2 months, three patients had stability, and four had a partial response for more than four months. 17 Currently, there is an ongoing Phase II clinical trial (ASLAN001), a pan-HER kinase inhibitor in refractory advanced or metastatic BTC (NCT02609958).
On the other hand, most of the data for neoadjuvant or conversion chemotherapy followed by surgery comes from small trials and case reports of BTC with advanced unresectable or metastatic disease. 4, [7] [8] [9] [10] 18, 19 None of these studies combined biological therapy with long-term and disease-free survival as the present case. Kato et al. 18 revealed that the neoadjuvant Gemcitabine regimen is able to downsize tumours towards resectable stages in up to 36.4% with a comparable survival to those who were resectable at first (45% vs. 40.8% survival at five years).
Even though the actual standard of care in unresectable BTC is Gemcitabine plus Cisplatin, 2 a prospective trial comparing Gemcitabine plus Cisplatin versus Gemcitabine alone, failed to demonstrate any differences in resection and survival rates. 
